acetylcysteine has been researched along with Schizophrenia in 60 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (10.00) | 29.6817 |
| 2010's | 34 (56.67) | 24.3611 |
| 2020's | 20 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kamińska, K; Lech, MA; Lorenc-Koci, E; Rogóż, Z | 1 |
| Cai, Y; Hu, Y; Huang, J; Shao, G; Su, Y; Xu, X; Zhang, M; Zhang, X; Zhou, H | 1 |
| Back, SE; Berk, M; Bradlow, RCJ; Kalivas, PW; Kanaan, RA | 1 |
| Green, MF; Hellemann, G; Lee, J; Maddock, RJ; Marder, SR; Yang, YS; Zhang, H | 1 |
| Berk, M; Bozaoglu, K; Castle, DJ; Dark, F; Dean, OM; Francis, PS; Galletly, C; Harris, A; Liu, D; Meyer, D; Neill, E; Phillipou, A; Rossell, SL; Sarris, J; Siskind, D; Yolland, C | 1 |
| Baskaran, R; Hwu, HG; Lai, CC; Lee, LJ; Liu, CM; Palani, M; Siow, PF; Tsao, CY; Tuan, LH | 1 |
| Andrade, C | 1 |
| Hatano, M; Iwata, N; Kishi, T; Sakuma, K | 1 |
| Benros, ME; Berk, M; Berna, F; Billeci, M; Boyer, L; Correll, CU; Fond, G; Fornaro, M; Kulkarni, J; Leboyer, M; Llorca, PM; Mallet, J; Misdrahi, D; Pignon, B; Rey, R; Schürhoff, F; Solmi, M; Sommer, IEC; Stahl, SM; Urbach, M | 1 |
| da Silva, FER; de Lucena, DF; Gama, CS; Gomes, NS; Lima, CNC; Macedo, DS; Miyajima, F; Monte, AS; Seeman, MV; Vasconcelos, GS; Vasconcelos, SMM | 1 |
| Bolu, A; Çelik, C; Uzun, Ö | 1 |
| Cohen, BM; Karmacharya, R; Kathuria, A; Lopez-Lengowski, K; McPhie, D; Watmuff, B | 1 |
| Barker, GJ; Collier, T; Egerton, A; Gabay, AS; Lally, J; Lay, A; Lythgoe, DJ; MacCabe, JH; McGuire, P; McQueen, G; Stone, JM | 1 |
| Barreiros, AR; Berk, M; Castle, DJ; Dean, OM; Hanratty, D; Hansen, A; Harris, AW; Neill, E; Phillipou, A; Rossell, SL; Siskind, D; Tan, EJ; Yolland, CO | 1 |
| Naguy, A; Naguy, C | 1 |
| Berk, M; Brown, E; Dean, OM; Dipnall, JF; Krägeloh, CU; McNamara, RK; Medvedev, ON; Narayanan, A; Sandham, MH; Siegert, RJ; Sumich, A | 1 |
| Blagonravova, AS; Mazo, GE; Mishanov, GA; Pyatoykina, AS; Semennov, IV; Zhilyaeva, TV | 1 |
| Martínez-Banaclocha, M | 1 |
| Alexandre, J; Chrétien, B; Dolladille, C; Fedrizzi, S; Lelong-Boulouard, V; Sassier, M | 1 |
| Cabungcal, JH; Cuenod, M; Do, KQ; Grace, AA; Uliana, DL; Zhu, X | 1 |
| Akasheh, N; Akbari, H; Heidary, M; Sepehrmanesh, Z | 1 |
| Berk, M; Cai, DB; Ng, CH; Ning, YP; Qiu, Y; Ungvari, GS; Xiang, YT; Yang, XH; Zhang, QE; Zheng, W | 1 |
| Alameda, L; Baumann, PS; Buclin, T; Cleusix, M; Conus, P; Cousins, A; Cuenod, M; Do, KQ; Eap, CB; Ferrari, C; Fournier, M; Gholam-Rezaee, M; Golay, P; Gruetter, R; Jenni, R; Keshavan, MS; Seidman, LJ; Wojcik, J; Woo, TW; Xin, L | 1 |
| Breier, A; Francis, MM; Hummer, TA; Liffick, E; Mehdiyoun, NF; Metzler, E; Visco, AC; Vohs, JL; Yang, Z; Zhang, Y | 1 |
| Castle, DJ; Dean, OM; Francis, PS; Galletly, C; Harris, AWF; Hughes, ME; Neill, E; Phillipou, A; Rossell, SL; Sarris, J; Siskind, D; Smith, ZM; Yolland, COB | 1 |
| Barker, GJ; Collier, T; Egerton, A; Lally, J; Lythgoe, DJ; MacCabe, JH; McGuire, P; McQueen, G; Stone, JM; Zelaya, F | 1 |
| Davis, MC; Green, MF; Hellemann, G; Marder, SR; Wynn, JK; Yang, YS | 1 |
| Koola, MM | 1 |
| Abi-Dargham, A; Baker, S; Gil, R; Girgis, RR; Gu, M; Javitt, DC; Kantrowitz, JT; Kegeles, LS; Mao, X; Ojeil, N; Shungu, DC; Spielman, DM; Xu, X | 1 |
| Ali, R; Zavodnick, AD | 1 |
| Hashimoto, K | 2 |
| Cabungcal, JH; Calhoon, GG; Counotte, DS; Cuenod, M; Do, KQ; Hong, LE; Kil, J; Lewis, E; O'Donnell, P; Piantadosi, P; Pollock, C; Presgraves, E; Sullivan, E; Tejeda, HA | 1 |
| Sawa, A; Seidman, LJ | 1 |
| Arroll, MA; Neil, J; Wilder, L | 1 |
| Berk, M; Bush, AI; Dean, OM; Dodd, S; Rapado-Castro, M; Venugopal, K | 1 |
| Bumb, JM; Enning, F; Leweke, FM | 1 |
| Racz, R; Sohoni, P; Sweet, BV | 1 |
| Berk, M; Bush, AI; Castle, DJ; Conus, P; Copolov, D; Cuénod, M; Dean, OM; Do, KQ; Mancuso, SG; Rossell, SL | 1 |
| Andreazza, AC; Berk, M; Dean, O; Kapczinski, F; Magalhães, PV | 1 |
| Dowling, NA; Lorains, FK; Merkouris, SS | 1 |
| Cserép, C; Freund, TF; Hegedüs, P; Nyiri, G; Otte, DM; Pósfai, B; Szabadits, E; Watanabe, M; Zimmer, A | 1 |
| Miyake, N; Miyamoto, S | 1 |
| Chen, AT; Chibnall, JT; Nasrallah, HA | 1 |
| Berk, M; Bozaoglu, K; Castle, DJ; Dark, F; Dean, O; Francis, PS; Galletly, C; Harris, A; Liu, D; Meyer, D; Neill, E; Phillipou, A; Rossell, SL; Sarris, J; Siskind, D | 1 |
| Berk, M; Bush, AI; Dean, OM; Dodd, S; Malhi, GS; On, ZX; Rapado-Castro, M; Skvarc, DR | 1 |
| Berk, M; Pantelis, C; Wood, SJ; Yücel, M | 1 |
| Altindag, A; Bulut, M; Dalkilic, A; Savas, HA; Virit, O | 1 |
| Anderson-Hunt, M; Berk, M; Bush, AI; Conus, P; Copolov, DL; Dean, O; Hanna, B; Jeavons, S; Katz, F; Kohlmann, K; Malhi, GS; Munib, A; Ng, F; Otmar, R; Schapkaitz, I | 1 |
| Berk, M; Bush, AI; Choy, KH; Dean, O; van den Buuse, M | 1 |
| Berk, M; Bush, AI; Copolov, DL; Dean, OM; Mavros, C; van den Buuse, M | 1 |
| Cuenod, M; das Neves Duarte, JM; Do, KQ; Gholam-Razaee, MM; Gruetter, R; Kulak, A | 1 |
| D'Souza, DC; Ford, JM; Gueorguieva, R; Gunduz-Bruce, H; Krystal, JH; Mathalon, DH; Oliver, S; Reinhart, RM; Roach, BJ | 1 |
| Carmeli, C; Cuénod, M; Do, KQ; Knyazeva, MG | 1 |
| Shungu, DC | 1 |
| Asevedo, E; Brietzke, E; Cunha, GR; Mansur, RB; Zugman, A | 1 |
| Baker, DA; Choi, S; Kong, L; Lutgen, V; Qualmann, K; Resch, J | 1 |
| Baker, DA; Haroutunian, V; Kristiansen, LV; Madayag, A; Meador-Woodruff, JH; Raju, I | 1 |
| Berk, M; Boulat, O; Bovet, P; Buclin, T; Bush, AI; Conus, P; Copolov, D; Cuénod, M; Deppen, P; Do, KQ; Fornari, E; Knyazeva, MG; Lavoie, S; Meuli, R; Murray, MM; Solida, A; Vianin, P | 1 |
| Anderson-Hunt, M; Berk, M; Bush, AI; Conus, P; Copolov, D; Cuenod, M; Dean, O; Do, KQ; Jeavons, S; Judd, F; Katz, F; Katz, P; Little, J; Lu, K; Ording-Jespersen, S; Schapkaitz, I | 1 |
20 review(s) available for acetylcysteine and Schizophrenia
| Article | Year |
|---|---|
The efficacy of nutritional supplements for the adjunctive treatment of schizophrenia in adults: A systematic review and network meta-analysis.
Topics: Acetylcysteine; Dietary Supplements; Fatty Acids, Omega-3; Humans; Network Meta-Analysis; Schizophrenia; Vitamin B 12; Vitamin D; Vitamins | 2022 |
The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders.
Topics: Acetylcysteine; Anxiety Disorders; Bipolar Disorder; Humans; Obsessive-Compulsive Disorder; Schizophrenia | 2022 |
Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia.
Topics: Acetylcysteine; Antipsychotic Agents; Clozapine; Humans; Schizophrenia | 2022 |
N-acetylcysteine for schizophrenia: A systematic review and meta-analysis.
Topics: Acetylcysteine; Humans; Schizophrenia | 2023 |
Adjunctive agents to antipsychotics in schizophrenia: a systematic umbrella review and recommendations for amino acids, hormonal therapies and anti-inflammatory drugs.
Topics: Acetylcysteine; Amino Acids; Anti-Inflammatory Agents; Antipsychotic Agents; Humans; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Schizophrenia | 2023 |
Meta-analysis of randomised controlled trials with
Topics: Acetylcysteine; Cognition; Humans; Memory, Short-Term; Psychotic Disorders; Randomized Controlled Trials as Topic; Schizophrenia | 2020 |
N-acetyl-cysteine in Schizophrenia: Potential Role on the Sensitive Cysteine Proteome.
Topics: Acetylcysteine; Antioxidants; Cysteine; Glutathione; Humans; Oxidation-Reduction; Proteome; Schizophrenia | 2020 |
N-acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acetylcysteine; Antioxidants; Bipolar Disorder; Depressive Disorder, Major; Humans; Randomized Controlled Trials as Topic; Schizophrenia | 2018 |
Improvement of cognitive function in schizophrenia with
Topics: Acetylcysteine; Cognition; Cognitive Dysfunction; Glutathione; Humans; Neuroprotective Agents; Oxidative Stress; Receptors, N-Methyl-D-Aspartate; Schizophrenia | 2020 |
N-Acetylcysteine and metabotropic glutamate receptors: implications for the treatment of schizophrenia: a literature review.
Topics: Acetylcysteine; Humans; Randomized Controlled Trials as Topic; Receptors, Ionotropic Glutamate; Receptors, Metabotropic Glutamate; Schizophrenia | 2014 |
Targeting of NMDA receptors in new treatments for schizophrenia.
Topics: Acetylcysteine; Animals; Antioxidants; Antipsychotic Agents; Drug Design; Glutathione; Humans; Molecular Targeted Therapy; Oxidative Stress; Receptors, N-Methyl-D-Aspartate; Schizophrenia | 2014 |
Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review.
Topics: Acetylcysteine; Antipsychotic Agents; Ascorbic Acid; Databases, Factual; Diet, Gluten-Free; Dietary Supplements; Fatty Acids, Unsaturated; Folic Acid; Glutamates; Humans; Melatonin; Oxidative Stress; Randomized Controlled Trials as Topic; Schizophrenia; Thioctic Acid; Vitamin B Complex; Vitamin D; Vitamin E | 2014 |
Drug repurposing and emerging adjunctive treatments for schizophrenia.
Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Cannabidiol; Dietary Supplements; Drug Repositioning; Drug Therapy, Combination; Fatty Acids, Omega-3; Hormones; Humans; Meta-Analysis as Topic; Quality of Life; Randomized Controlled Trials as Topic; Schizophrenia | 2015 |
Oral acetylcysteine for neuropsychiatric disorders.
Topics: Acetylcysteine; Administration, Oral; Autistic Disorder; Bipolar Disorder; Complementary Therapies; Dietary Supplements; Humans; Mental Disorders; Obsessive-Compulsive Disorder; Schizophrenia; Trichotillomania | 2015 |
Antioxidant treatments for schizophrenia.
Topics: Acetylcysteine; Allopurinol; Antioxidants; Antipsychotic Agents; Ascorbic Acid; Dehydroepiandrosterone; Drug Therapy, Combination; Free Radical Scavengers; Ginkgo biloba; Humans; Oxidative Stress; Randomized Controlled Trials as Topic; Schizophrenia; Selegiline; Vitamin E; Vitamins | 2016 |
Interventions for comorbid problem gambling and psychiatric disorders: Advancing a developing field of research.
Topics: Acetylcysteine; Antimanic Agents; Antipsychotic Agents; Anxiety Disorders; Behavior Therapy; Bipolar Disorder; Citalopram; Cognitive Behavioral Therapy; Comorbidity; Free Radical Scavengers; Gambling; Humans; Lithium Compounds; Mental Disorders; Motivational Interviewing; Naltrexone; Narcotic Antagonists; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Tobacco Use Disorder | 2016 |
[Effectiveness of N-acetylcysteine in the treatment of schizophrenia].
Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents; Antioxidants; Clinical Trials as Topic; Disease Models, Animal; Glutathione; Humans; Microglia; Neuroprotective Agents; Oxidative Stress; Schizophrenia | 2016 |
Placebo-controlled augmentation trials of the antioxidant NAC in schizophrenia: A review.
Topics: Acetylcysteine; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Free Radical Scavengers; Humans; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Schizophrenic Psychology | 2016 |
Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress.
Topics: Acetylcysteine; Glutathione; Humans; Magnetic Resonance Imaging; Mitochondrial Diseases; Nervous System; Oxidative Stress; Schizophrenia | 2009 |
N-acetylcysteine as a potentially useful medication to prevent conversion to schizophrenia in at-risk individuals.
Topics: Acetylcysteine; Animals; Disease Progression; Free Radical Scavengers; Humans; Risk; Schizophrenia | 2012 |
17 trial(s) available for acetylcysteine and Schizophrenia
| Article | Year |
|---|---|
N-Acetylcysteine effects on glutathione and glutamate in schizophrenia: A preliminary MRS study.
Topics: Acetylcysteine; Glutamic Acid; Glutathione; Humans; Psychotic Disorders; Schizophrenia | 2022 |
N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms.
Topics: Acetylcysteine; Antipsychotic Agents; Australia; Clozapine; Double-Blind Method; Humans; Quality of Life; Schizophrenia; Treatment Outcome | 2022 |
Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia.
Topics: Acetylcysteine; Adult; Brain; Cross-Over Studies; Double-Blind Method; Female; Gyrus Cinguli; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Net; Proton Magnetic Resonance Spectroscopy; Rest; Schizophrenia | 2020 |
[The double-blind randomized placebo-controlled trial of N-acetylcysteine use in schizophrenia: preliminary results].
Topics: Acetylcysteine; Antipsychotic Agents; Drug Therapy, Combination; Humans; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome | 2020 |
Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial.
Topics: Acetylcysteine; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2018 |
N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis.
Topics: Acetylcysteine; Adolescent; Adult; Antioxidants; Biomarkers; Cognitive Dysfunction; Double-Blind Method; Female; Glutathione; Glutathione Peroxidase; Humans; Magnetic Resonance Spectroscopy; Male; Outcome Assessment, Health Care; Oxidation-Reduction; Prefrontal Cortex; Psychotic Disorders; Schizophrenia; Young Adult | 2018 |
Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders.
Topics: Acetylcysteine; Adult; Antipsychotic Agents; Brain; Cognition; Double-Blind Method; Female; Humans; Magnetic Resonance Imaging; Male; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome; Young Adult | 2018 |
N-acetylcysteine improves EEG measures of auditory deviance detection and neural synchronization in schizophrenia: A randomized, controlled pilot study.
Topics: Acetylcysteine; Adult; Cognition; Double-Blind Method; Electroencephalography; Electroencephalography Phase Synchronization; Evoked Potentials, Auditory; Female; Free Radical Scavengers; Humans; Male; Middle Aged; Pilot Projects; Schizophrenia; Schizophrenic Psychology | 2019 |
Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: A pilot in vivo proton magnetic resonance spectroscopy study.
Topics: Acetylcysteine; Adolescent; Adult; Female; Free Radical Scavengers; Glutamic Acid; Glutathione; Gyrus Cinguli; Humans; Male; Middle Aged; Prefrontal Cortex; Proton Magnetic Resonance Spectroscopy; Schizophrenia; Young Adult | 2019 |
Towards stage specific treatments: effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia.
Topics: Acetylcysteine; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Schizophrenia; Time Factors; Treatment Outcome; Young Adult | 2015 |
N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms.
Topics: Acetylcysteine; Adolescent; Adult; Aged; Antipsychotic Agents; Australia; Clozapine; Double-Blind Method; Drug Resistance; Female; Follow-Up Studies; Free Radical Scavengers; Humans; Male; Middle Aged; New Zealand; Quality of Life; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult | 2016 |
Cognitive effects of adjunctive N-acetyl cysteine in psychosis.
Topics: Acetylcysteine; Adult; Attention; Bipolar Disorder; Cognitive Dysfunction; Executive Function; Female; Free Radical Scavengers; Humans; Male; Memory, Short-Term; Middle Aged; Psychotic Disorders; Schizophrenia; Treatment Outcome | 2017 |
Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia.
Topics: Acetylcysteine; Adult; Data Collection; Double-Blind Method; Female; Free Radical Scavengers; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 2011 |
Glutamatergic modulation of auditory information processing in the human brain.
Topics: Acetylcysteine; Adult; Behavior; Cognition; Electroencephalography; Event-Related Potentials, P300; Evoked Potentials, Auditory; Excitatory Amino Acid Antagonists; Female; Free Radical Scavengers; Humans; Ketamine; Male; Memory; Psychomotor Performance; Reaction Time; Receptors, N-Methyl-D-Aspartate; Schizophrenia | 2012 |
Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial.
Topics: Acetylcysteine; Adult; Biomarkers; Cross-Over Studies; Double-Blind Method; Electroencephalography; Female; Free Radical Scavengers; Glutathione; Humans; Male; Models, Statistical; Multivariate Analysis; Oscillometry; Oxidation-Reduction; Placebos; Schizophrenia; Signal Processing, Computer-Assisted | 2012 |
Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients.
Topics: Acetylcysteine; Acoustic Stimulation; Adult; Brain Mapping; Cerebral Cortex; Contingent Negative Variation; Cross-Over Studies; Discrimination, Psychological; Double-Blind Method; Electroencephalography; Evoked Potentials, Auditory; Female; Free Radical Scavengers; Glutathione; Humans; Male; Middle Aged; Neuropsychological Tests; Reaction Time; Retrospective Studies; Schizophrenia; Time Factors | 2008 |
N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial.
Topics: Acetylcysteine; Adult; Analysis of Variance; Double-Blind Method; Female; Free Radical Scavengers; Humans; Male; Middle Aged; Movement Disorders; Outcome Assessment, Health Care; Psychiatric Status Rating Scales; Schizophrenia | 2008 |
23 other study(ies) available for acetylcysteine and Schizophrenia
| Article | Year |
|---|---|
N-Acetylcysteine and Aripiprazole Improve Social Behavior and Cognition and Modulate Brain BDNF Levels in a Rat Model of Schizophrenia.
Topics: Acetylcysteine; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cognition; Cognition Disorders; Disease Models, Animal; Female; Hippocampus; Prefrontal Cortex; Pregnancy; Quinolones; Rats; Rats, Sprague-Dawley; Schizophrenia; Social Behavior | 2022 |
Chronic N-Acetylcysteine Treatment Prevents Amphetamine-Induced Hyperactivity in Heterozygous
Topics: Acetylcysteine; Amphetamine; Animals; Disease Models, Animal; Dopamine; Female; Glycogen Synthase Kinase 3; Humans; Mice; Nerve Tissue Proteins; Pregnancy; Receptors, Dopamine; Schizophrenia | 2022 |
Sex influences in the preventive effects of N-acetylcysteine in a two-hit animal model of schizophrenia.
Topics: Acetylcysteine; Age Factors; alpha7 Nicotinic Acetylcholine Receptor; Animals; Corpus Striatum; Female; Glutathione; Hippocampus; Lipid Peroxidation; Locomotion; Male; Memory, Short-Term; Nitrites; Parvalbumins; Poly I-C; Prefrontal Cortex; Rats; Receptors, G-Protein-Coupled; Schizophrenia; Sensory Gating; Sex Characteristics; Social Interaction; Stress, Psychological | 2020 |
Effect of N-acetylcysteine on clozapine-induced sialorrhea in schizophrenic patients: a case series.
Topics: Acetylcysteine; Adult; Clozapine; Female; Humans; Male; Middle Aged; Schizophrenia; Sialorrhea | 2020 |
Synaptic deficits in iPSC-derived cortical interneurons in schizophrenia are mediated by NLGN2 and rescued by N-acetylcysteine.
Topics: Acetylcysteine; Antioxidants; Cell Adhesion Molecules, Neuronal; Cells, Cultured; Cerebral Cortex; Humans; Induced Pluripotent Stem Cells; Interneurons; Nerve Tissue Proteins; Neural Stem Cells; Schizophrenia; Synapses | 2019 |
N-acetyl-cysteine in schizophrenia-there is more than meets the eyes!
Topics: Acetylcysteine; Antipsychotic Agents; Humans; Schizophrenia | 2021 |
A novel way to quantify schizophrenia symptoms in clinical trials.
Topics: Acetylcysteine; Adolescent; Adult; Aged; Antipsychotic Agents; Attention; Clinical Trials as Topic; Delusions; Female; Free Radical Scavengers; Guilt; Hallucinations; Humans; Male; Middle Aged; Mood Disorders; Patient Outcome Assessment; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Young Adult | 2021 |
Could N-acetylcysteine improve the safety of clozapine?
Topics: Acetylcysteine; Antipsychotic Agents; Clozapine; Humans; Schizophrenia; Schizophrenia, Treatment-Resistant | 2021 |
Thalamic reticular nucleus impairments and abnormal prefrontal control of dopamine system in a developmental model of schizophrenia: prevention by N-acetylcysteine.
Topics: Acetylcysteine; Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Methylazoxymethanol Acetate; Rats; Schizophrenia; Thalamic Nuclei | 2021 |
Effects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia.
Topics: Acetylcysteine; Adult; Brain; Caudate Nucleus; Cerebrovascular Circulation; Creatine; Cross-Over Studies; Double-Blind Method; Female; Glutamic Acid; Gyrus Cinguli; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Proton Magnetic Resonance Spectroscopy; Regional Blood Flow; Rest; Schizophrenia | 2018 |
Antipsychotic-minocycline-acetylcysteine combination for positive, cognitive, and negative symptoms of schizophrenia.
Topics: Acetylcysteine; Animals; Anti-Bacterial Agents; Antipsychotic Agents; Drug Therapy, Combination; Free Radical Scavengers; Humans; Minocycline; Schizophrenia | 2019 |
Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia.
Topics: Acetylcysteine; Animals; Animals, Newborn; Antioxidants; Disease Models, Animal; Dopamine Agonists; Drug Administration Schedule; Excitatory Amino Acid Agonists; Excitatory Postsynaptic Potentials; Female; Gene Expression Regulation, Developmental; Hippocampus; Ibotenic Acid; In Vitro Techniques; Neurons; Pregnancy; Quinpirole; Rats; Rats, Sprague-Dawley; Reflex, Startle; Schizophrenia | 2014 |
Is prophylactic psychiatry around the corner? combating adolescent oxidative stress for adult psychosis and schizophrenia.
Topics: Acetylcysteine; Animals; Antioxidants; Female; Gene Expression Regulation, Developmental; Pregnancy; Schizophrenia | 2014 |
Benefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophrenia.
Topics: Acetylcysteine; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Humans; Schizophrenia; Treatment Outcome | 2015 |
Synaptic and cellular changes induced by the schizophrenia susceptibility gene G72 are rescued by N-acetylcysteine treatment.
Topics: Acetylcysteine; Animals; Carrier Proteins; Dentate Gyrus; Entorhinal Cortex; Free Radical Scavengers; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, Transgenic; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Schizophrenia; Synapses | 2016 |
Regarding "N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial".
Topics: Acetylcysteine; Double-Blind Method; Free Radical Scavengers; Glutathione; Humans; Randomized Controlled Trials as Topic; Schizophrenia | 2008 |
Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia.
Topics: Acetylcysteine; Adult; Antipsychotic Agents; Benzodiazepines; Clopenthixol; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Female; Free Radical Scavengers; Humans; Olanzapine; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology | 2009 |
Effects of N-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats.
Topics: Acetylcysteine; Animals; Antioxidants; Behavior, Animal; Cerebrum; Corpus Striatum; Cyclohexanones; Dose-Response Relationship, Drug; Exploratory Behavior; Frontal Lobe; Glutathione; Hippocampus; Male; Memory Disorders; Memory, Short-Term; Neurons; Neuroprotective Agents; Oxidative Stress; Random Allocation; Rats; Rats, Sprague-Dawley; Schizophrenia | 2010 |
N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: relevance to schizophrenia and bipolar disorder.
Topics: Acetylcysteine; Animals; Bipolar Disorder; Brain; Corpus Striatum; Cyclohexanones; Dextroamphetamine; Disease Models, Animal; Frontal Lobe; Glutathione; Male; Rats; Rats, Sprague-Dawley; Schizophrenia | 2011 |
N-acetylcysteine normalizes neurochemical changes in the glutathione-deficient schizophrenia mouse model during development.
Topics: Acetylcysteine; Alanine; Animals; Aspartic Acid; Cerebral Cortex; Disease Models, Animal; Free Radical Scavengers; Glutamate-Cysteine Ligase; Glutamic Acid; Glutamine; Glutathione; Inositol; Lactic Acid; Longitudinal Studies; Magnetic Resonance Spectroscopy; Mice; Mice, Knockout; Schizophrenia | 2012 |
N-acetylcysteine for the treatment of glutathione deficiency and oxidative stress in schizophrenia.
Topics: Acetylcysteine; Animals; Cerebral Cortex; Free Radical Scavengers; Glutamate-Cysteine Ligase; Glutathione; Schizophrenia | 2012 |
Reduction in phencyclidine induced sensorimotor gating deficits in the rat following increased system xc⁻ activity in the medial prefrontal cortex.
Topics: Acetylcysteine; Amino Acid Transport System y+; Amino Acid Transport Systems, Acidic; Animals; Benzoates; Disease Models, Animal; Dose-Response Relationship, Drug; Gait Disorders, Neurologic; Glycine; In Situ Hybridization; Male; Phencyclidine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Reflex, Startle; RNA, Messenger; Schizophrenia; Sensory Gating | 2013 |
Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Amino Acids; Analysis of Variance; Animals; Behavior, Animal; Cell Line, Transformed; Disease Models, Animal; Dose-Response Relationship, Drug; Extracellular Fluid; Female; Free Radical Scavengers; Glutamic Acid; Glycine; Humans; Interpersonal Relations; Male; Maze Learning; Microdialysis; Phencyclidine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Schizophrenia; Xanthenes | 2008 |